Related papers: An Executable Specification of Oncology Dose-Escal…
Randomized discontinuation design (RDD) is an enrichment strategy commonly used to address limitations of traditional placebo-controlled trials, particularly the ethical concern of prolonged placebo exposure. RDD consists of two phases: an…
The US Food and Drug Administration launched Project Optimus with the aim of shifting the paradigm of dose-finding and selection towards identifying the optimal biological dose that offers the best balance between benefit and risk, rather…
Several Prolog implementations include a facility for tabling, an alternative resolution strategy which uses memoisation to avoid redundant duplication of computations. Until relatively recently, tabling has required either low-level…
PRholog is an experimental extension of logic programming with strategic conditional transformation rules, combining Prolog with Rholog calculus. The rules perform nondeterministic transformations on hedges. Queries may have several results…
In this paper, I propose to implement syllabification in OT as a parser. I propose several innovations that result in a finite and small candidate set. The candidate set problem is handled with several moves: i) MAX and DEP violations are…
Phase I dose-finding trials in oncology seek to find the maximum tolerated dose (MTD) of a drug under a specific schedule. Evaluating drug-schedules aims at improving treatment safety while maintaining efficacy. However, while we can…
An early phase clinical trial is the first step in evaluating the effects in humans of a potential new anti-disease agent or combination of agents. Usually called "phase I" or "phase I/II" trials, these experiments typically have the…
Constrained Markov Decision Processes are a class of stochastic decision problems in which the decision maker must select a policy that satisfies auxiliary cost constraints. This paper extends upper confidence reinforcement learning for…
Phase I oncology trials aim to identify a safe dose - often the maximum tolerated dose (MTD) - for subsequent studies. Conventional designs focus on population-level toxicity modeling, with recent attention on leveraging pharmacokinetic…
This manuscript introduces an \proglang{R} package called \pkg{trialr} that implements a collection of clinical trial methods in \proglang{Stan} and \proglang{R}. In this article, we explore three methods in detail. The first is the…
Higher-order constructs extend the expressiveness of first-order (Constraint) Logic Programming ((C)LP) both syntactically and semantically. At the same time assertions have been in use for some time in (C)LP systems helping programmers…
More than 200 generic drugs approved by the U.S. Food and Drug Administration for non-cancer indications have shown promise for treating cancer. Due to their long history of safe patient use, low cost, and widespread availability,…
Approximate linear programming (ALP) and its variants have been widely applied to Markov Decision Processes (MDPs) with a large number of states. A serious limitation of ALP is that it has an intractable number of constraints, as a result…
This work introduces the Burdened Bayesian Logistic Regression Model (BBLRM), an enhancement of the Bayesian Logistic Regression Model (BLRM) for dose-finding in phase I oncology trials. The BLRM determines the maximum tolerated dose (MTD)…
For the misspecified linear Markov decision process (MLMDP) model of Jin et al. [2020], we propose an algorithm with three desirable properties. (P1) Its regret after $K$ episodes scales as $K \max \{ \varepsilon_{\text{mis}},…
Higher-order constructs extend the expressiveness of first-order (Constraint) Logic Programming ((C)LP) both syntactically and semantically. At the same time assertions have been in use for some time in (C)LP systems helping programmers…
The estimand framework included in the addendum to the ICH E9 guideline facilitates discussions to ensure alignment between the key question of interest, the analysis, and interpretation. Therapeutic knowledge and drug mechanism play a…
An accurately identified maximum tolerated dose (MTD) serves as the cornerstone of successful subsequent phases in oncology drug development. Bayesian logistic regression model (BLRM) is a popular and versatile model-based dose-finding…
Extrachromosomal DNA (ecDNA) represents one of the most pressing challenges in cancer biology: circular DNA structures that amplify oncogenes, evade targeted therapies, and drive tumor evolution in ~30% of aggressive cancers. Despite its…
The traditional more-is-better dose selection paradigm, developed based on cytotoxic chemotherapeutics, is often problematic When applied to the development of novel molecularly targeted agents (e.g., kinase inhibitors, monoclonal…